These results demonstrate that p190BCR-ABL-specific CTLs are capable of controlling treatment-refractory Ph+ ALL in vivo, and they support the development of adoptive immunotherapeutic approaches with BCR-ABL CTLs in Ph+ ALL. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.